Currently Viewing:
In Focus Blog
Currently Reading
Myriad Acquires Maker of EndoPredict Breast Cancer Prognostic Test
June 01, 2016 – Mary Caffrey
ACLU Complaint Against Myriad Genetics Suggests Broader Campaign to Compel Data Sharing
May 20, 2016 – Mary Caffrey
Aetna to Stay in ACA Markets, May Add More States
May 12, 2016 – Mary Caffrey
Smokers Who Lie Cause Higher Health Costs for Everyone Else, Report Finds
May 05, 2016 – Mary Caffrey
Blueprint for a Revolution in Paying Physicians: CMS Proposes MACRA Regulations
April 28, 2016 – Mary Caffrey
Under Pressure, CMS Delays Hospital Quality Ratings Release
April 21, 2016 – Mary Caffrey
CMS Expands Alternate Payment Model for Primary Care Doctors
April 11, 2016 – Mary Caffrey
Florida Settles Long-Running Case Over Children's Medicaid
April 07, 2016 – Mary Caffrey
Medicare to Fund Diabetes Prevention Programs, Burwell Says
March 23, 2016 – Mary Caffrey

Myriad Acquires Maker of EndoPredict Breast Cancer Prognostic Test

Mary Caffrey
The acquisition lets Myriad acquire the maker of EndoPredict, which just received reimbursement status from Aetna and meets ASCO guidelines for payment by Medicare contractors.
Myriad Genetics announced Tuesday it had acquired Sividon Diagnostics, the maker of EndoPredict, a test that predicts progression of breast cancer and fits with the company’s strategy to produce molecular diagnostics for every step in healthcare, from gauging risk to deciding treatment.

The purchase, for approximately $39.2 million US dollars, allows for up to $16.8 million more in performance-based payments. Myriad was already Sividon’s partner for marketing EndoPredict in Europe, and the acquisition comes as the test is gaining reimbursement status in the United States. Aetna covers the test, and payment from Medicare contractors is anticipated, due to support in guidelines from the American Society of Clinical Oncology.

In a statement, Myriad President and CEO Mark C. Capone said EndoPredict will be “the foundational product” of the company’s transition to kit-based tests, which allow the diagnostic test to be evaluated in a hospital instead of the test material being shipped to a specialized laboratory. Myriad is “transitioning the product to the Thermo Fisher QuantStudio platform as a key step in the international kit strategy,” the statement said.

EndoPredict is backed by 5 studies involving 4000 patients and has been used by 13,000 patients worldwide. A leading prognostic test, it gauges breast cancer aggressiveness and guides patients whether to pursue chemotherapy. It fits with the company’s “4-in-6” strategy of creating tests that (1) evaluate risk of disease (2) confirm diagnosis (3) establish prognosis and (4) select therapy. Myriad seeks to cover this ground across 6 therapeutic areas: oncology, urology, preventive care, dermatology, autoimmune disease, and neuroscience.

“Sividon brings to Myriad the best-in-class breast cancer prognosis test and strengthens our market leading oncology portfolio of high value personalized medicine products,” Capone said.

Christoph Petry, CEO of Sividon Diagnostics, said Myriad had strengths in the regulatory, reimbursement and commercialization areas to bring the test to a larger market, which both companies feel is poised to grow.

Outside the United States, EndoPredict will seek coverage status in the United Kingdom, Canada, and Germany during 2016.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up